Powder: -20°C for 3 years | In solvent: -80°C for 1 year
α-Cyano-4-hydroxycinnamic acid (α-Cyano-4-hydroxycinnamic acid(α-CHCA)) 是非竞争性单羧酸盐转运蛋白 (MCTs) 抑制剂,可抑制线粒体丙酮酸转运蛋白,Ki 值为 6.3 μM。它可作为基质辅助激光解吸电离-飞行时间质谱 (MALDI-TOF) 分析的基质,可以促进肽离子化。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
50 mg | ¥ 313 | 现货 | ||
100 mg | ¥ 453 | 现货 | ||
200 mg | ¥ 659 | 待询 | ||
1 mL * 10 mM (in DMSO) | ¥ 185 | 现货 |
产品描述 | α-Cyano-4-hydroxycinnamic acid (α-Cyano-4-hydroxycinnamic acid(α-CHCA)) (α-CHCA) is an inhibitor of monocarboxylate transporter 1 (MCT1) that blocks pyruvate transport in rat heart mitochondria (IC50 : 1.5 μM). |
体外活性 | The effectiveness of CHC in glioma cells appears to be dependent on Monocarboxylate transporters (MCTs) membrane expression.?MCT1 downregulation showed similar effects on different glioma cells, supporting CHC as an MCT1 inhibitor.?There was a synergistic effect when combining CHC with temozolomide treatment in U251 cells.?In the CAM in vivo model, CHC decreased the size of tumors and the number of blood vessels formed[1]. |
细胞实验 | Cells were plated into 96-well plates, at a density of 3 × 10^3 cells per well.?The effect of treatment with CHC (0.6–12 mM) on cell number (total biomass) was determined at 24, 48, and 72 h by the?sulforhodamine B assay (SRB, TOX-6).?IC50 values (CHC concentration that corresponds to 50% of cell growth inhibition) were estimated from 3 independent experiments, each one in triplicate, using GraphPad Software.?Cell proliferation assay was performed as previously described32 and assessed under the treatment conditions previously described, for 5 mM and 10 mM of CHC.?After CHC treatment, cells were incubated with BrdU and its incorporation was assessed at 450 nm (λref = 655 nm) .?Cell growth (total biomass) and cell proliferation for glioma siMCT1 cells and the effect of CHC (1.25–15 mM) on cell number were performed[1]. |
别名 | α-Cyano-4-hydroxycinnamic acid(α-CHCA), 2-氰基-4-羟基 |
分子量 | 189.17 |
分子式 | C10H7NO3 |
CAS No. | 28166-41-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 37mg/mL(195.59mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 5.2863 mL | 26.4313 mL | 52.8625 mL | 132.1563 mL |
5 mM | 1.0573 mL | 5.2863 mL | 10.5725 mL | 26.4313 mL | |
10 mM | 0.5286 mL | 2.6431 mL | 5.2863 mL | 13.2156 mL | |
20 mM | 0.2643 mL | 1.3216 mL | 2.6431 mL | 6.6078 mL | |
50 mM | 0.1057 mL | 0.5286 mL | 1.0573 mL | 2.6431 mL | |
100 mM | 0.0529 mL | 0.2643 mL | 0.5286 mL | 1.3216 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
α-Cyano-4-hydroxycinnamic acid 28166-41-8 Membrane transporter/Ion channel Monocarboxylate transporter matrix-assisted MALDI-TOF matrix Inhibitor lactate a-Cyano-4-hydroxycinnamic acid applications MCTs pyruvate laser desorption α-Cyano-4-hydroxycinnamic acid(α-CHCA) spectrometry ionization Monocarboxylate Transporter a-Cyano-4-hydroxycinnamic acid(a-CHCA) transporter α Cyano 4 hydroxycinnamic acid 2-氰基-4-羟基 peptide inhibit alpha-Cyano-4-hydroxycinnamic acid alpha-Cyano-4-hydroxycinnamic acid(alpha-CHCA) αCyano4hydroxycinnamic acid facilitate inhibitor